Document:

Prepared by MERRILL CORPORATION

QuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

EXHIBIT 10.37    
  

 
  AMENDMENT NO. 1 TO THE TULARIK INC.
  1997 EQUITY INCENTIVE PLAN    
  

    At
a meeting of the Compensation Committee of the Board of Directors of Tularik Inc. on June 14, 2001, the following amendment to the Tularik Inc. 1997 Equity
Incentive Plan (the "Plan") was adopted, effective as of December 12, 1999: 

    Section 2(l)
of the Plan is hereby deleted in its entirety and replaced with the following: 

    "(a) "Fair Market Value" means, as of any date, the value of the common stock of the Company determined as follows (and
in each case prior to the Listing Date, in a manner consistent with Section 260.140.50 of Title 10 of the California Code of Regulations). 

    (1) If
the common stock is listed on any established stock exchange or traded on the Nasdaq National Market or the Nasdaq SmallCap Market, the Fair Market Value of a
share of common stock shall be the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on such exchange or market (or the exchange or market with the greatest
volume of trading in the Company's common stock) on the day of determination (the most recent day prior to the day of determination, if the day of determination is not a day on which reported sales
and bids occurred), as reported in The Wall Street Journal or such other source as the Board deems reliable. 

    (2) In
the absence of such markets for the common stock, the Fair Market Value shall be determined in good faith by the Board or any Committee to which responsibility
for administration of the Plan has been delegated pursuant to subsection 3(c)." 

    Except
as amended above, the Plan remains in full force and effect. 

    The
undersigned hereby certifies that the foregoing is true, correct and complete. 

	

 /s/ WILLIAM J. RIEFLIN   
 William J. Rieflin

Executive Vice President, Administration,

General Counsel and Secretary	
 	

 

1

QuickLinks

EXHIBIT 10.37

AMENDMENT NO. 1 TO THE TULARIK INC. 1997 EQUITY INCENTIVE PLANPrepared by MERRILL CORPORATION

QuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

EXHIBIT 10.38    
  

 
  AMENDMENT NO. 1 TO LICENSING AGREEMENT
  BETWEEN TULARIK INC. AND ELI LILLY AND COMPANY    
  

    THIS AMENDMENT NO. 1 (this "Amendment") to the Licensing Agreement dated as of September 30,
1999 (the "Agreement") by and between Eli Lilly And Company, an Indiana corporation, having offices at Lilly Corporate Center, Indianapolis, Indiana 46285 ("Lilly"), and Tularik Inc., a Delaware
corporation having offices at Two Corporate Drive, South San Francisco, California 94080 ("Tularik"), is entered into as of January 10, 2001. Lilly and Tularik may be referred to herein individually
as a "Party" or, collectively, as "Parties". 

    WHEREAS, the Parties previously entered into the Agreement, which provided for the licensing of the Product from Lilly to Tularik; 

    WHEREAS, the Parties desire to modify the Agreement to clarify certain aspects of Section 2.2 of the Agreement; 

    WHEREAS, in order to accomplish the foregoing, the Parties have agreed to amend the Agreement in part; 

    NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements expressed herein, and for other good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, Tularik and Lilly hereby agree as follows: 

    1.  Section
2.2 of the Agreement is hereby amended by adding the following two paragraphs: 

    "Lilly
agrees that any and all discoveries, inventions, improvements, trade secrets, know-how, works of authorship or other intellectual property conceived, created, written,
developed or first reduced to practice by employees of Lilly, alone or jointly with others, in the course of providing assistance regarding the Product to Tularik pursuant to this section
("Inventions") shall be the sole and exclusive property of Tularik. Lilly acknowledges that all original works of authorship protectable by copyright which are produced by employees of Lilly in the
course of providing assistance regarding the Product to Tularik pursuant to this section are "works made for hire," as defined in the United States Copyright Act (17 U.S.C. § 101). 

    Lilly
shall promptly and fully disclose to Tularik all Inventions, shall treat all Inventions as Tularik Proprietary Information subject to Section 6.3 of this Agreement, and hereby
agrees to assign to Tularik without further consideration all of Lilly's right, title and interest in and to any and all Inventions, whether or not patentable or copyrightable. Lilly and its employees
shall execute all papers, including patent applications, invention assignments and copyright assignments, and otherwise shall assist Tularik as reasonably required to perfect in Tularik the rights,
title and other interests granted to Tularik under this Agreement. Tularik shall pay for costs related to such assistance if it is required." 

    2.  Section
8.1(f)(4) of the Agreement is hereby amended by replacing the last sentence of such Section 8.1(f)(4) with the following: 

Without
limiting the generality of the foregoing, no termination of this Agreement, whether by lapse of time or otherwise, shall serve to terminate the obligations of the Parties hereto under
subsections 2.2 (last two paragraphs), 3.4, 3.5, 6.3, 6.6, 6.7, 6.14, Section 7 (as provided in Section 7.5), subsections 8.1(e), 8.1(f) and Section 9 (except for subsection 9.4, which shall expire as
provided therein) hereof, and such obligations shall survive any such termination. 

    3.  Capitalized
terms used herein but not otherwise defined herein shall have the respective meanings assigned to such terms in the Agreement. 

1

 

    4.  Except as expressly modified by this Amendment, all of the terms and conditions of the Agreement shall remain in full force and effect. 

    5.  This
Amendment may be executed in two or more counterparts, each of which shall be deemed an original but all of which shall be considered one and the same
instrument. 

    IN WITNESS WHEREOF, the parties have executed, or caused their duly authorized officer or representative to execute, this Amendment as
of January 10, 2001. 

	TULARIK INC.	 	 
	

By:	
 	

  /s/ WILLIAM J. RIEFLIN   
	
 	

 
	Name: William J. Rieflin

Title: Executive Vice President	 	 
	
ELI LILLY AND COMPANY INC.	
 	

 
	

By:	
 	

  /s/ HOMER PEARCE   
	
 	

 
	Name: Homer Pearce

Title: Vice President, Cancer Research/Clinical Investigation

2

QuickLinks

EXHIBIT 10.38

AMENDMENT NO. 1 TO LICENSING AGREEMENT BETWEEN TULARIK INC. AND ELI LILLY AND COMPANYPrepared by MERRILL CORPORATION

QuickLinks
 -- Click here to rapidly navigate through this document

  

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.  

  
 

    EXHIBIT 10.39    
  

 
 

AMENDMENT NO. 2 TO COLLABORATION AGREEMENT
  BETWEEN TULARIK INC. AND JAPAN TOBACCO INC.    
  

    THIS AMENDMENT NO. 2  (this "Amendment") to the Collaboration Agreement dated as of
June 1, 2000 (the "Agreement") by and between Japan Tobacco Inc., a Japanese corporation, having offices at JT Building, 2-1 Toranomon, 2-chome,
Minato-ku, Tokyo 105, Japan ("JT"), and Tularik Inc., a Delaware corporation having offices at Two Corporate Drive, South San Francisco, California 94080 ("Tularik"), is entered
into as of May 31, 2001. JT and Tularik may be referred to herein as a "Party" or, collectively, as "Parties". 

    WHEREAS, the Parties previously entered into the Agreement, which provided for a collaborative program between JT and Tularik to
research, discover, develop, manufacture and market products that agonize or antagonize various Program Targets for the treatment of disease in humans; 

    WHEREAS, Tularik has established the Subsidiary to conduct a portion of such collaborative program; 

    WHEREAS, the Parties desire to modify the Agreement to clarify certain provision of the Agreement relating to the support for the
Research Program; 

    WHEREAS, in order to accomplish the foregoing, the Parties have agreed to amend the Agreement in part; 

    NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements expressed herein, and for other good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, Tularik and JT hereby agree as follows: 

    1.  Section 6.1(b)
of the Agreement is hereby amended by deleting the last sentence of Section 6.1(b). 

    2.  For
the purpose of clarification of Section 6.1(b)(B), Section 6.1 of the Agreement is hereby further amended by inserting the following as
Section 6.1(g) and (h): 

(g)
JT shall pay to Tularik [*] to support the Research Program during the period from [*]. Tularik represents that the attached Exhibit A
reflects: (i) [*] the conduct of the Research Program during the period from [*]; and (ii) [*] the conduct of the
Research Program [*] during the period from [*]. 

(h)
Tularik covenants and agrees to provide to [*] on or before [*] a revised version of Exhibit A (the "Revised Exhibit") reflecting:
(i) [*] the conduct of the Research Program during the period from [*]; and (ii) the [*] during the period from
[*]. The [*] shall advise Tularik and JT on or before [*] whether such [*] reasonably believes that the
[*]. Then, by [*], the Parties shall mutually discuss in good faith by taking into consideration [*] and
[*], and either agree upon (i) the [*]; or (ii) a [*] during the period from [*];  provided, however, that the  [*] shall in no event be
less than
[*]. If the sum of the [*], and the [*] from [*] is greater than or equal to
[*], JT shall pay to Tularik [*] to support the Research Program during the period from [*] on or before
[*]. If the sum of the [*], and the [*] from [*] is less than  
[*], JT shall [*] amount equal to (i) [*]; multiplied by (ii) [*]. JT shall pay to Tularik
[*], to support the Research Program during the period from [*] on or before [*]. In the event that the
[*] from [*], Tularik shall [*] an amount equal to (i) [*]; multiplied by
(ii) [*]. At the option of JT, any [*] calculated pursuant to the immediately preceding sentence: (i) shall be
[*]; or (ii) shall be [*] support 

1

 

for the Research Program [*] due to Tularik by JT for the period from [*], unless otherwise agreed by the Parties. If the attested report of each year
pursuant to [*] shows any [*] from each of [*] report provided by Tularik without such attest, such [*],
in a reasonable time frame. 

    3.  Capitalized
terms used herein but not otherwise defined herein shall have the respective meanings assigned to such terms in the Agreement. 

    4.  Except
as expressly modified by this Amendment, all of the terms and conditions of the Agreement shall remain in full force and effect. 

    5.  This
Amendment may be executed in two or more counterparts, each of which shall be deemed an original but all of which shall be considered one and the same
instrument. 

    IN WITNESS WHEREOF, the parties have executed, or caused their duly authorized officer or representative to execute, this Amendment as
of May 31, 2001. 

	TULARIK INC.	 	 
	

By:	
 	

/s/ David V. Goeddel
	
 	

 
	Name: David V. Goeddel, Ph.D.

Title: Chief Executive Officer	 	 
	
JAPAN TOBACCO INC.	
 	

 
	

By:	
 	

/s/ Takashi Kato
	
 	

 
	Name: Takashi Kato

Title: Managing Director, Pharmaceutical Division	 	 

2

 
 
 

Exhibit A    
  

    [*] 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

3

QuickLinks

EXHIBIT 10.39

AMENDMENT NO. 2 TO COLLABORATION AGREEMENT BETWEEN TULARIK INC. AND JAPAN TOBACCO INC.

Exhibit A

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}]]